The Society for Functional Precision Medicine

The Society for Functional Precision Medicine

The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Dr. Letai will serve as NCI’s 18th director.

The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals

Key PointsBlast-specific ex vivo venetoclax sensitivity correlated strongly with treatment responses and predicted longer survival.VenEx trial showed that

Logun et al. report a unique phase 1 clinical trial design with parallel assessment of patients and rapidly generated patient-derived tumor organoids for CAR-T cell bioactivity in glioblastoma. They showed that cytokine release and the degree of cytolysis in glioblastoma organoids with autologous CAR-T treatment correlated with clinical patient metrics.

The SFPM Seminar series is for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

The SFPM arose to match cancer patients to their best therapies. Using patient-derived models, including organoids and 2D culture; and many readouts, including metabolic, morphologic and cell death m...

The SFPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients ...